ARIX.L

Arix Bioscience Plc
Unaudited NAV for November 2022
12th December 2022, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.

Arix Bioscience PLC (ARIX)
Unaudited NAV for November 2022

12-Dec-2022 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Arix Bioscience plc

 

Unaudited NAV for November 2022

 

LONDON, 12 December 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited Net Asset Value (“NAV”) of the Company for the date ended 30 November 2022 as follows:

 

Date

NAV Breakdown

Total NAV

 

NAV per share

Listed Portfolio

Unlisted Portfolio

Cash

Other Interests

30 November 22

(unaudited)

£41.8m

£57.1m

£130.0m

£1.9m

£230.8m

£1.79

 

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 
ISIN: GB00BD045071
Category Code: NAV
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
Sequence No.: 207309
EQS News ID: 1508581

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1508581&application_name=news&site_id=acquiremedia3]]>
TwitterFacebookLinkedIn